☆ 4.6 Article

Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma-Importance of Good Liver Function and Good Performance Status

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study

Naoya Kato et al.

Summary: Cabozantinib demonstrated efficacy and manageable safety profile in Japanese patients with advanced HCC. The median PFS was 7.4 months in the prior-sorafenib cohort and 3.6 months in the sorafenib-naive cohort. Disease control rate was 85.0% and 64.3% in the prior-sorafenib and sorafenib-naive cohorts, respectively. The most common adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified.

HEPATOLOGY RESEARCH (2023)

添加到收藏夹

Article Oncology

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study

Toshifumi Tada et al.

Summary: The aim of this study was to investigate whether the neo-GPS could predict prognosis in HCC patients treated with Atez/Bev. The results showed that the neo-GPS was independently associated with overall survival and performed better than the traditional GPS in predicting prognosis.

CANCER MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma

Tetsu Tomonari et al.

Summary: This study analyzed the clinical outcomes of Cabozantinib (CAB) in patients with unresectable hepatocellular carcinoma (uHCC) and compared treatment outcomes between the full-dose and reduced-dose groups. The study found that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial and that dose reduction of CAB may be a safer treatment option.

HEPATOLOGY RESEARCH (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Kazuki Maesaka et al.

Summary: This study aimed to assess the impact of antibiotic use on therapeutic response in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. The results showed that prior antibiotic use was associated with reduced therapeutic responses.

PLOS ONE (2023)

添加到收藏夹

Review Oncology

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy

Takeshi Hatanaka et al.

Summary: Systemic therapy for advanced-stage hepatocellular carcinoma (HCC) is undergoing major changes due to advancements in molecular-targeted therapies and immune checkpoint inhibitors (ICIs). Transarterial chemoembolization (TACE) has been the standard treatment for intermediate-stage HCC, but it now includes molecular-targeted drugs and ICIs. However, there is controversy regarding the appropriate regimen and order of drug administration for intermediate-stage HCC, as it encompasses a wide variety of HCCs.

CANCERS (2023)

添加到收藏夹

Article Oncology

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

Robin Kate Kelley et al.

Summary: The study demonstrates the beneficial effects of cabozantinib in patients with advanced HCC, irrespective of ALBI grade 1 or 2.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Review Oncology

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review

Chih-Hung Hsu et al.

Summary: AXL and MET play key roles in the progression, treatment resistance, and immunomodulation of HCC. Continued development of drugs that target these receptor tyrosine kinases appears likely to represent a useful strategy to improve outcomes for patients with HCC.

LIVER CANCER (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Anthony B. El-Khoueiry et al.

Summary: This retrospective analysis evaluated the efficacy of cabozantinib in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh B liver cirrhosis. The results showed that cabozantinib improved overall survival and progression-free survival in these patients, with a safety profile consistent with the overall population.

BMC CANCER (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old

Rui Sato et al.

Summary: This study aimed to compare the use of sorafenib and lenvatinib in elderly patients with hepatocellular carcinoma (HCC) in terms of overall survival (OS) and rate of adverse events (AEs)-induced discontinuation of molecular targeted agents (MTAs). The study found that sorafenib may be more desirable for HCC patients over 80 years old due to lower rates of discontinuation and higher rates of subsequent MTT.

HEPATOLOGY RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade)

Kazuya Kariyama et al.

Summary: This study developed a simplified scoring system (ALBS) to predict the prognosis of patients with hepatocellular carcinoma treated with lenvatinib. The results showed that the ALBS grade had a good ability to stratify LEN-HCC prognosis, and its predictive ability was comparable to mALBI.

JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Oncology

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Xavier Adhoute et al.

Summary: This study aimed to evaluate the progression-free survival (PFS) of REG and CBZ as second-line therapy for advanced HCC. The results showed no significant difference in PFS between the two drugs. The study also identified elevated levels of inflammatory markers and AST as predictive factors for non-control of TKIs over time.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma

Michael H. Storandt et al.

Summary: This study retrospectively analyzed the clinical outcomes of patients with advanced hepatocellular carcinoma who received cabozantinib after progression on immunotherapy. The study found that patients may benefit from treatment with cabozantinib following progression on immunotherapy, and most patients had a manageable side effect profile.

CANCERS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

Masatoshi Kudo et al.

Summary: Cabozantinib 60 mg/day showed favorable efficacy and safety profile for Japanese patients with advanced hepatocellular carcinoma (HCC) who had previously received one or two lines of systemic anticancer therapy including sorafenib, especially for those who had received prior sorafenib treatment.

JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Letter Oncology

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

A. Vogel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma

Teiji Kuzuya et al.

Summary: This study found that early changes in alpha-fetoprotein levels may be useful for predicting treatment efficacy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. An AFP ratio of 1.4 or higher at 3 weeks could be an early predictor of refractoriness to this therapy.

ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Lorenza Rimassa et al.

Summary: Cabozantinib showed improved overall survival and progression-free survival versus placebo in previously treated advanced hepatocellular carcinoma patients, with various biomarkers favoring low and high baseline concentrations. Some biomarkers may serve as favorable prognostic factors, but none were predictive of treatment benefit. Cabozantinib-induced pharmacodynamic changes in biomarkers were observed, but not associated with patient survival.

LIVER CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation A STROBE-compliant retrospective observational study

Hisanori Muto et al.

Summary: In patients with advanced HCC and liver occupation >= 50%, transient deteriorated ALBI scores and elevated CRP levels may be important factors to consider in obtaining an antitumor response of PR + SD during MTA treatment.

MEDICINE (2021)

添加到收藏夹

Article Oncology

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study

Kaoru Tsuchiya et al.

Summary: The first-line systemic therapy for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab therapy, and lenvatinib has shown high response rates in real-world practice for unresectable HCC patients in Japan. Pretreatment factors like ALBI score, AFP levels, and major vascular invasion play crucial roles in treatment strategy decisions for these patients.

CANCERS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database

Atsushi Hiraoka et al.

Summary: This study investigated the relationship between ALBI grade and sequential treatment for advanced hepatocellular carcinoma in Japanese clinical practice. The results indicate that adequate liver function, as indicated by ALBI grade, at the start and end of first-line treatment is associated with successful sequential therapy in Japanese clinical practice.

DRUGS-REAL WORLD OUTCOMES (2021)

添加到收藏夹

Article Oncology

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Francesco Tovoli et al.

Summary: Real-life data of cabozantinib for hepatocellular carcinoma in Italy showed comparable efficacy and safety with its registration trial. Factors such as macrovascular invasion, performance status, and alpha-fetoprotein level were associated with worse overall survival, while discontinuation for intolerance and absence of new extrahepatic lesions at progression were linked to better outcomes for patients.

LIVER CANCER (2021)

添加到收藏夹

Article Oncology

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Fabian Finkelmeier et al.

Summary: This study reported real-world data from an international cohort of patients with advanced HCC treated with cabozantinib, showing efficacy and safety in patients with compensated cirrhosis. The median overall survival was 9.7 months in Child-Pugh A patients and 3.4 months in Child-Pugh B patients. Cabozantinib treatment was effective and safe in these patients.

LIVER CANCER (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma

Teiji Kuzuya et al.

HEPATOLOGY RESEARCH (2020)

添加到收藏夹

Article Oncology

Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression

Rongdang Fu et al.

MEDICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

Robin Kate Kelley et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

Robin Kate Kelley et al.

ESMO OPEN (2020)

添加到收藏夹

Article Oncology

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

David J. Pinato et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis

Atsushi Hiraoka et al.

CANCER MEDICINE (2019)

添加到收藏夹

Article Oncology

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study

Kazuomi Ueshima et al.

CANCERS (2019)

添加到收藏夹

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

Linh Nguyen et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

Masatoshi Kudo et al.

JOURNAL OF GASTROENTEROLOGY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression

Murugabaskar Balan et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

添加到收藏夹

Article Oncology

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade

Philip J. Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma

Teiji Kuzuya et al.

PLOS ONE (2015)

添加到收藏夹

Article Oncology

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

Qingfeng Xiang et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Comparison of standard-dose and half-dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis

Hiroki Nishikawa et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Anna R. Kwilas et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Biophysics

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

Y. Kanda

BONE MARROW TRANSPLANTATION (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score

A. Hollebecque et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.